Vertex Pharmaceuticals (VRTX)
AI-powered earnings call analysis for Vertex Pharmaceuticals. Get insights from quarterly earnings reports with our AI-generated podcast. Educational content only - not investment advice.
Subscribe
Subscribe
Get Episode Notifications
Get an email when new Vertex Pharmaceuticals earnings episodes are released.
Latest Episode
Q3 2026 Earnings
6:09 • 11/3/2026
All Episodes
Q3 2026 Earnings
6:09Vertex achieved 12% Q3 revenue growth across diversified products, raised FY2026 guidance to $13.15-$13.25B, and completed $9.0B Crinetics acquisition.
Q2 2026 Earnings
6:42Vertex delivered strong Q2 2026 with $3.3B revenue (+12% YoY) and raised FY2026 guidance to $13.1-13.2B, driven by CF leadership, growing CASGEVY and JOURNAVX momentum, and Povi's FDA acceptance for IgAN.
Q1 2026 Earnings
7:46Vertex achieved strong Q1 2026 results with $2.99B revenue (+8% YoY) and $4.47 adjusted EPS, driven by CF leadership and rapid commercial uptake of new therapies KASJEVY and GERNAVICS, while povitacicept demonstrated compelling Phase III IgAN efficacy with fastest BLA filing in company history.
Q4 2025 Earnings
8:06AI-generated analysis of VRTX's Q4 2025 earnings call.
